These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21997232)

  • 1. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS; McGarry A; Ma Q; Kieburtz K
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
    de Tommaso M; Specchio N; Sciruicchio V; Difruscolo O; Specchio LM
    Mov Disord; 2004 Dec; 19(12):1516-8. PubMed ID: 15390067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
    Curtis A; Mitchell I; Patel S; Ives N; Rickards H
    Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current clinical management of Huntington's disease.
    Phillips W; Shannon KM; Barker RA
    Mov Disord; 2008 Aug; 23(11):1491-504. PubMed ID: 18581443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral symptoms associated with Huntington's disease.
    Anderson KE; Marshall FJ
    Adv Neurol; 2005; 96():197-208. PubMed ID: 16383221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms.
    Johnston TG
    Int Clin Psychopharmacol; 2011 Mar; 26(2):114-9. PubMed ID: 21119522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monozygotic twins suffering from Huntington's disease show different cognitive and behavioural symptoms.
    Gómez-Esteban JC; Lezcano E; Zarranz JJ; Velasco F; Garamendi I; Pérez T; Tijero B
    Eur Neurol; 2007; 57(1):26-30. PubMed ID: 17108691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drug therapies in Huntington's disease.
    Mason SL; Barker RA
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):273-97. PubMed ID: 19453283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options for Huntington's disease.
    Grimbergen YA; Roos RA
    Curr Opin Investig Drugs; 2003 Jan; 4(1):51-4. PubMed ID: 12625029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
    Heitz F; La Rosa S; Gonzalez-Couto E; Gaviraghi G; Terstappen GC
    IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New symptomatic therapies for Huntington disease.
    Deb A; Frank S; Testa CM
    Handb Clin Neurol; 2017; 144():199-207. PubMed ID: 28947118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based approach in the treatment of Huntington's disease.
    Mestre TA; Ferreira JJ
    Parkinsonism Relat Disord; 2012 May; 18(4):316-20. PubMed ID: 22177624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Huntington chorea. Clinical correlations and preliminary neuropsychological data].
    Fragassi NA; Stanzione M; Angelini R; Di Maio L
    Acta Neurol (Napoli); 1992; 14(4-6):530-6. PubMed ID: 1293994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of change in early Huntington's disease: a clinicometric analysis.
    Meyer C; Landwehrmeyer B; Schwenke C; Doble A; Orth M; Ludolph AC;
    Mov Disord; 2012 Jan; 27(1):118-24. PubMed ID: 22095693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?
    Killoran A; Biglan KM
    Mov Disord; 2014 Sep; 29(11):1404-13. PubMed ID: 25164707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zotepine in Huntington's disease.
    Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
    Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perospirone in treatment of Huntington's disease: a first case report.
    Roppongi T; Togo T; Nakamura S; Asami T; Yoshimi A; Shiozaki K; Kato D; Kawanishi C; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):308-10. PubMed ID: 16887250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease: looking beyond the movement disorder.
    Morreale MK
    Adv Psychosom Med; 2015; 34():135-42. PubMed ID: 25832519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of clozapine in the treatment of movement disorders.
    Factor SA; Friedman JH
    Mov Disord; 1997 Jul; 12(4):483-96. PubMed ID: 9251065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
    Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
    Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.